Haemophilia Foundation Australia

Recent papers from Haemophilia Foundation Australia

1. Current Status of National Haemophilia Registries in the Asia–Pacific Region: An AHAD‐AP Registry Committee SurveyHaemophilia · 2026
2. Extravascular distribution of factor IX—review of experimental and clinical evidence, and relevance for hemophilia B replacement therapyResearch and Practice in Thrombosis and Haemostasis · 2026
3. Italian Patients Journey for Gene Therapy in Haemophilia AHaemophilia · 2026
4. Sebetralstat for breakthrough attacks in patients with hereditary angioedema receiving long-term prophylaxis in KONFIDENT-SJournal of Allergy and Clinical Immunology Global · 2026
5. Optimizing Perioperative Management of Haemophilia B With rFIX‐FP: Pharmacokinetic Validation of the Hemoptidose ToolHaemophilia · 2026
6. Garadacimab for the long-term prophylaxis of hereditary angioedema.2026
7. The Swiss Haemophilia Registry–Report From the First 8 YearsHaemophilia · 2026
8. The Value of Public Inquiries, Ethical Accountability, and Patient Voices: Reflections on the Infected Blood InquiryHaemophilia · 2026
9. The 2025 WAO Guidelines for the classification, diagnosis, and treatment of hereditary angioedema, with consideration of worldwide disparitiesWorld Allergy Organization Journal · 2026
10. Disease burden and unmet medical need in severe hemophilia in Greece: insights from clinicians and patientsFrontiers in Public Health · 2026
11. Five‐Year Experience of Haemophilia Centre Certification Performed by the German, Austrian and Swiss Society for Thrombosis and Haemostasis ResearchHaemophilia · 2025
12. Physical Activity in People with HemophiliaSeminars in Thrombosis and Hemostasis · 2025
13. Sebetralstat for On‐Demand Treatment of Mucosal Hereditary Angioedema Attacks in KONFIDENT‐SClinical and Translational Allergy · 2025
14. Platelet Releasate Reprograms Synovial Macrophages In Vitro: A New Approach in the Treatment of Hemophilic SynovitisInternational Journal of Molecular Sciences · 2025
15. The WFH Guidelines for the Management of Haemophilia: AAV Gene Therapy, 2025Haemophilia · 2025
16. HAEMFIX: Impact of Switching From SHL‐FIX to EHL‐FIX in Patients With Haemophilia BHaemophilia · 2025
17. Management of von Willebrand Disease With a Factor VIII‐Poor von Willebrand Factor Concentrate: Results From the Paediatric Cohort of a Prospective Observational Post‐Marketing StudyHaemophilia · 2025
18. Emicizumab utilization, safety, and outcomes in people with severe hemophilia and no inhibitors: 3-year follow-up. A report from the UK Haemophilia Centre Doctors’ OrganisationResearch and Practice in Thrombosis and Haemostasis · 2025
19. Frailty and frailty syndromes in persons with hemophilia: a reviewJournal of Thrombosis and Haemostasis · 2025
20. Recombinant Adeno-Associated Virus Integration Profiles in Nonhuman Primates and Gene Therapy Participants after Treatment with Valoctocogene RoxaparvovecHuman Gene Therapy · 2025